ngscog | 1044

NGS Colorectal Cancer (expanded panel)

Keywords

BRAF, Colon, colorectal carcinoma, HER2, KRAS, MLH1, MSH2, MSH6, MSI, Next Generation Sequencing, NRAS, PIK3CA, PMS2, POLD1, POLE, TMB, TP53, Trusight, TSO

Material

Tissue biopsy
Tube sterile, white (32)

Note

Full gene sequencing: BRAF, KRAS, MLH1, MSH2, MSH6, NRAS, PIK3CA, PMS2, POLD1, POLE, TP53 as well as the Solid Tumor DNA Panel (523 genes) and Solid Tumor Fusion panel (54 genes), Immunohistochemistry: HER2. Additionally, microsatellite instability (MSI) and tumor mutational burden (TMB) are reported. | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since, in rare cases, findings may also indicate hereditary changes, the Federal Act on Human Genetic Testing (HGTA) requires that patients be appropriately informed (see www.viollier.ch/consent_ssmg). The consent form is intended for internal documentation within the practice and does not need to be submitted to Viollier. Billing: in accordance with TARDOC.

Duration

10 days

Frequency

1 x per week

Method

Next Generation Sequencing

Price

CHF 0.00

Tariff

0.00 TP

Team of consultants

Dr. med. Katharina Marston FMH Pathology, molecular pathology	FMH Pathology, molecular pathology	T +41 61 486 10 34
Dr. rer. nat. Henriette Kurth FAMH Specialist in laboratory medicine, medical genetics	FAMH Specialist in laboratory medicine, medical genetics	T +41 61 486 14 78
Dr. med. Jean-François Egger FMH pathology	FMH pathology	T +41 22 789 63 63
PD Dr. med. Andreas Zettl FMH pathology, molecular pathology	FMH pathology, molecular pathology	T +41 61 486 10 12
Dr. med. Santiago Giménez de Mestral FMH pathology, cytopathology	FMH pathology, cytopathology	T +41 22 789 63 36